SCHEMBL14525852

SCHEMBL14525852

c1ccc2c(-c3c4ccccc4c(-c4ccc(-c5nccnc5-c5ccc(-c6c7ccccc7c(-c7cccc8ccccc78)c7ccccc67)cc5)cc4)c4ccccc34)cccc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.43
GSK3B P49841 1/20 0.41
CDK5 Q00535 1/20 0.41
CDK5R1 Q15078 1/20 0.41
MAPK13 O15264 1/20 0.40
GCGR P47871 1/20 0.40
MAPK12 P53778 1/20 0.40
MAPK11 Q15759 1/20 0.40
MAPK14 Q16539 1/20 0.40
DHFR P00374 1/20 0.40
NISCH Q9Y2I1 1/20 0.38
KDM4E B2RXH2 6/20 0.38
ALDH1A1 P00352 5/20 0.38
MAPT P10636 5/20 0.38
HPGD P15428 4/20 0.38
HSD17B10 Q99714 4/20 0.38
NPC1 O15118 4/20 0.38
MAPK1 P28482 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
RAB9A P51151 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14525862 0.84 CA12 (0.51) BCHEGSK3BCDK5CDK5R1MAPK13
SCHEMBL29751906 0.84 CA12 (0.49) DHFRKDM4EALDH1A1MAPTHPGD
SCHEMBL16814673 0.84 CA12 (0.49) DHFRKDM4EALDH1A1MAPTHPGD
SCHEMBL14228010 0.83 L3MBTL1 (0.44) MAPK14DHFRKDM4EALDH1A1MAPT
SCHEMBL3925327 0.82 CA12 (0.51) DHFRENPP3ENPP1CA12CA1
SCHEMBL9612925 0.81 MAPT (0.53) BCHEMAPK13GCGRMAPK12MAPK11
SCHEMBL9613128 0.81 TNF (0.43) BCHEMAPK11MAPK14KDM4EALDH1A1
SCHEMBL24662849 0.81 BCHE (0.50) BCHEGSK3BCDK5CDK5R1DHFR
SCHEMBL14461161 0.81 MAPT (0.55) BCHEMAPK13GCGRMAPK12MAPK11
SCHEMBL9612929 0.81 KDM4E (0.51) DHFRKDM4EALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070080628-A1 Electroluminescent devices comprising 2-(p-triphenyl)-3-phenyl-pyrazine derivatives CIBA SPECIALTY CHEMICALS CORP. 2007-04-12 US disclosed
US-20070080628-A1 Electroluminescent devices comprising 2-(p-triphenyl)-3-phenyl-pyrazine derivatives CIBA SPECIALTY CHEMICALS CORP. 2007-04-12 US disclosed
EP-1687856-B1 ELECTROLUMINESCENT DEVICES COMPRISING 2-(P-TRIPHENYL)-3-PHENYL-PYRAZINE DERIVATIVES CIBA SC HOLDING AG (CH) 2007-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070080628-A1 Electroluminescent devices comprising 2-(p-triphenyl)-3-phenyl-pyrazine derivatives C1S, TYR, C5 BCHE 3214/4885GSK3B 4766/4885CDK5 188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.